Antismoking drug comes under scrutiny after deathsBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7284.452/b (Published 24 February 2001) Cite this as: BMJ 2001;322:452
- Roger Dobson
The manufacturer of the antismoking drug amfebutamone (Zyban), GlaxoSmithKline, has insisted that no evidence exists of an increased risk of death with its use, after 18 deaths were linked with suspected adverse drug reactions. The Medicines Control Agency said that the contribution of amfebutamone to the deaths is unknown.
“It should be noted that …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial